Aug 20, 2026
Immutep Corporate Presentation
Jun 04, 2026
EULAR 2026 – IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic
May 31, 2026
ASCO 2026 – Eftilagimod alfa, an APC activator via MHC class II, induced lymphocyte activation linked to improved survival in metastatic cancer patients
Feb 20, 2026
Dec 02, 2025
SABCS 2025 – Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003
Nov 13, 2025
CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)
Oct 19, 2025
ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)
Oct 18, 2025
ESMO Congress 2025 – INSIGHT-003 (First Line Non-Small Cell Lung Cancer)
ESMO Congress 2025 – TACTI-004 (First Line Non-Small Cell Lung Cancer)
Dec 12, 2024
ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)
Nov 22, 2024
2024 AGM CEO Presentation
Nov 13, 2024
CTOS 2024 Annual Meeting – EFTISARC-NEO trial of neoadjuvant soluble LAG-3 protein (Soft Tissue Sarcoma)
